BioAdaptives Announces Aug. 1 Launch of XcellaraHeart Cardiovascular Supplement Combining Stem Cell Mobilization with Tanshinone IIA

BioAdaptives, Inc. (OTC: BDPT) has announced the commercial launch of XcellaraHeart, a cardiovascular wellness supplement set to be available for order on Aug. 1, 2026, with initial deliveries expected in early August. The product combines the company's Xcellara stem/progenitor cell mobilization formula with Tanshinone IIA, a bioactive compound derived from Danshen root, to target cardiovascular repair biology.

The Xcellara base formula, which has been the subject of a randomized, double-blind, placebo-controlled clinical trial, demonstrated an average 268.8% increase in circulating primitive stem/progenitor-type cells after four weeks with zero adverse effects on more than twenty blood parameters. Tanshinone IIA has been studied for its effects on the SDF-1α/CXCR4 signaling pathway, which plays a role in cellular trafficking and cardiovascular repair. According to the company, XcellaraHeart is designed around a two-part strategy: mobilizing stem and progenitor cells and supporting cardiovascular signaling.

BioAdaptives has made a scientific evidence dossier detailing the formulation available on the company's product website at products.xcellara.com/science. The dossier distinguishes between what has been demonstrated in BioAdaptives' human clinical research on the Xcellara base, published research on Tanshinone IIA, and the company's product-development rationale for combining the two.

The launch of XcellaraHeart expands BioAdaptives' Xcellara product line, which includes seven targeted formulas combining the clinically proven mobilization base with tissue-specific signaling ingredients for cardiac, joint, neural, dermal, longevity, and stress-resilience applications. The company's flagship Xcellara base formula is described as the only dietary supplement with a human randomized, double-blind, placebo-controlled clinical trial showing a 268.8% increase in circulating hematopoietic stem and progenitor cells.

BioAdaptives is the developer of the Xcellara line of stem cell mobilization and tissue-homing supplements. Additional information about the company can be found at www.bioadaptives.com. The full press release is available at https://nnw.fm/G14S7.